



Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?

Charlotte Laloux, Flore Gouel, Cédrick Lachaud, Kelly Timmerman, Bruce Do Van, Aurélie Jonneaux, Maud Petrault, G Garcon, Nathalie Rouaix, Caroline Moreau, et al.

► To cite this version:

Charlotte Laloux, Flore Gouel, Cédrick Lachaud, Kelly Timmerman, Bruce Do Van, et al.. Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?. *Neurobiology of Disease*, 2017, 10.1016/j.nbd.2017.03.013 . inserm-01500610

HAL Id: inserm-01500610

<https://inserm.hal.science/inserm-01500610>

Submitted on 3 Apr 2017


HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?

C. Laloux, F. Gouel, C. Lachaud, K. Timmerman, B. Do Van, A. Jonneaux, M. Petrault, G. Garcon, N. Rouaix, C. Moreau, R. Bordet, J.A. Duce, J.C. Devedjian, D. Devos



PII: S0969-9961(17)30061-X
DOI: doi: [10.1016/j.nbd.2017.03.013](https://doi.org/10.1016/j.nbd.2017.03.013)
Reference: YNBDI 3927

To appear in: *Neurobiology of Disease*

Received date: 2 March 2017
Revised date: 21 March 2017
Accepted date: 26 March 2017

Please cite this article as: C. Laloux, F. Gouel, C. Lachaud, K. Timmerman, B. Do Van, A. Jonneaux, M. Petrault, G. Garcon, N. Rouaix, C. Moreau, R. Bordet, J.A. Duce, J.C. Devedjian, D. Devos , Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ynbdi(2017), doi: [10.1016/j.nbd.2017.03.013](https://doi.org/10.1016/j.nbd.2017.03.013)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Continuous cerebroventricular administration of dopamine:
A new treatment for severe dyskinesia in Parkinson's disease?**

Laloux C¹, Gouel F¹, Lachaud C¹, Timmerman K¹, Do Van B¹, Jonneaux A¹, Petrault M¹,
Garcon G³, Rouaix N², Moreau C¹, Bordet R¹, Duce J.A^{4,5*}, Devedjian JC^{1*}, Devos D^{1*}

1. Département de Pharmacologie médicale, INSERM UMRS-1171, Université Lille Nord de France, CHRU de Lille, Faculté de médecine, Pôle Recherche, 1 place de Verdun 59045 Lille cedex FRANCE.
2. Service de biochimie, dosage des catécholamines, et biologie moléculaire, CHRU de Lille, FRANCE
3. Institut Pasteur de Lille, EA4483-IMPECS, Université Lille Nord de France, CHRU de Lille, Faculté de médecine, Pôle Recherche, Lille, FRANCE.
4. School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, UK.
5. Oxidation Biology Unit, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, AUSTRALIA

*** Co-last authors**

Corresponding author:

Devos David, MD, PhD, Département de Pharmacologie Médicale, Université Lille Nord de France, CHRU de Lille, F-59037 Lille, France. david.devos@chru-lille.fr

Statistics: Title, 120 characters; running title, 37 characters; main text, 3314 words; abstract, 234 words; 1 table; 4 figures; 30 references.

Supplemental data: 1 supplementary table, 1 supplemental material, 1 video

Running title: Cerebral administration of dopamine for PD

Keywords: Parkinson's disease – dopamine – L-dopa related motor complications – treatment –disease modifying effect

Financial Disclosure/Conflict of Interest: none

Funding: This academic study was funded by a PHRC grant from the French Ministry of Health and France Parkinson.

Abstract

In Parkinson's disease (PD) depletion of dopamine in the nigro-striatal pathway is a main pathological hallmark that requires continuous and focal restoration. Current predominant treatment with intermittent oral administration of its precursor, Levodopa (L-dopa), remains the gold standard but pharmacological drawbacks trigger motor fluctuations and dyskinesia. Continuous intracerebroventricular (i.c.v.) administration of dopamine previously failed as a therapy because of an inability to resolve the accelerated dopamine oxidation and tachyphylaxia. We aim to overcome prior challenges by demonstrating treatment feasibility and efficacy of continuous i.c.v. of dopamine close to the striatum. Dopamine prepared either anaerobically (A-dopamine) or aerobically (O-dopamine) in the presence or absence of a conservator (sodium metabisulfite, SMBS) was assessed upon acute MPTP and chronic 6-OHDA lesioning and compared to peripheral L-dopa treatment. A-dopamine restored motor function and induced a dose dependent increase of nigro-striatal tyrosine hydroxylase positive neurons in mice after 7 days of MPTP insult that was not evident with either O-dopamine or L-dopa. In the 6-OHDA rat model, continuous circadian i.c.v injection of A-dopamine over 30 days also improved motor activity without occurrence of tachyphylaxia. This safety profile was highly favorable as A-dopamine did not induce dyskinesia or behavioral sensitization as observed with peripheral L-dopa treatment. Indicative of a new therapeutic strategy for patients suffering from L-dopa related complications with dyskinesia, continuous i.c.v of A-dopamine has greater efficacy in mediating motor impairment over a large therapeutic index without inducing dyskinesia and tachyphylaxia.

Abbreviations : Dopamine, DA; i.c.v., intra-cerebro-ventricular; L-dopa, Levodopa; MPTP, 1-méthyl-4-phenyl-1,2,3,6 tetrahydropyridine; 6-OHDA, 6-hydroxydopamine; PD, Parkinson's disease; SMBS, Sodium metabisulfite; SNpc, Substantia nigra *pars compacta*

Introduction

Parkinson's disease (PD) is the second most frequent neurodegenerative disorder worldwide. The loss of dopamine through denervation in the striatum as a result of progressive neuronal degeneration in the substantia nigra pars compacta (SNpc), is the primary neurotransmitter marker of the disease (de Lau and Breteler, 2006). Since dopamine does not cross the digestive mucosa or the blood brain barrier, its lipophilic precursor L-dopa has been employed and remains the pivotal oral medication (Chaudhuri and Schapira, 2009). However, after persistent use over several years, many pharmacokinetic drawbacks contribute to the occurrence of motor fluctuations and dyskinesia (Fahn and Parkinson study group, 2005). Indeed L-dopa has a short half-life, limited and variable reabsorption through the digestive and blood brain barriers and potentially harmful peripheral distribution. Moreover, L-dopa requires the aromatic L-amino acid decarboxylase for the synthesis of dopamine, which declines in the striatum with disease progression (Ciesielska *et al.*, 2015).

Under normal conditions, dopaminergic neurons of the SNpc generate a short phasic discharge firing pattern. The frequency and duration of this pattern embeds them in the tonic low-frequency background range and maintains the striatal dopamine concentration at a relatively constant level (Paladini and Roeper 2014). However, in the dopamine-depleted state relevant to PD, intermittent oral doses of L-dopa can induce discontinuous stimulation of striatal dopamine receptors that in turn contribute to dysfunctional dopaminergic pathways. Thus, continuous dopamine administration is considered more physiologically appropriate by preventing oscillations in neurotransmitter concentration (Olanow *et al.*, 2006, Gershanik and Jenner, 2012). De Yebenes *et al.* (1987) previously demonstrated that intracerebroventricular (i.c.v.) administered dopamine with an anti-oxidant adjuvant (sodium metabisulfite; SMBS) transiently improved motor handicap and increased dopamine in rat brains with unilateral neurotoxin 6-hydroxydopamine (6-OHDA)-induced damage as well as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxicated monkeys. The clinical feasibility of this administrative route has been supported by two PD patient case reports of dopamine infusion to the frontal ventricle, whereby a reduction in motor handicap was observed (Venna *et al.*, 1984; Horne *et al.*, 1989). However, both preclinical and clinical reports also highlight two overriding problems that prevented further development; (i) occurrence of tachyphylaxia and (ii) oxidation of dopamine causing enhanced dopamine metabolism and oxidative stress.

Dopamine oxidation can be limited by preparing, storing and administering dopamine in very low oxygen conditions. In addition, greater advances in programmable pumps now

minimize tachyphylaxia by allowing administration of a lower effective dopamine dose in accordance with the circadian cycle. The purpose of this study is to demonstrate that continuous circadian i.c.v. administration of dopamine close to the striatum is feasible, efficient and safe in mouse and rat models of PD, supporting clinical development of this strategy to be revisited in PD patients with L-dopa related complications with dyskinesia.

Material and methods

LUHMES cells

Lund human mesencephalic (LUHMES) cells (gift from Pr. Marcel Leist; CAAT, University of Konstanz, Germany) were grown for 2 days in differentiation medium (advanced DMEM/F12, $1 \times N2$ supplement, 2 mM l-glutamine, 1 mM cAMP, 1 μ g/ml tetracycline and 2 ng/ml recombinant GDNF) before seeding in 6 or 24 well plates and grown for a further 3 days before treatment. See supplementary material for details.

After 5 days of differentiation, LUHMES cells were treated with 1-methyl-4-phenylpyridinium (MPP⁺; 5 μ M) for 24 hours (h) before exposure to dopamine or L-3,4-dihydroxyphenylalanine (L-dopa)(Sigma Aldrich, St Louis, MO, USA) for a further 24h. Viability was measured on 10,000 cells by flow cytometry (CANTO II) using propidium iodide (0.5 μ M) and analysed with DIVA software (BD Biosciences, Le pont de Claix, France).

Rodent neurotoxic models

All experiments were carried out in accordance with the recommendations for the care and use of laboratory animals (FELASA) as well as European Directive 86/609-2010/63/UE guidelines for animal experimentation. Protocols were approved by an Ethical Committee (Nord-Pas-de-Calais;CEEA75) to induce MPTP neurotoxicity on 5 month old C57Bl/6J mice (Ethical permit number: CEEA102012) or 6-OHDA neurotoxicity in 5 month old Wistar rats (Ethical permit number: CEEA 262011 and CEEA2016020911207601). Animals were group-housed (10 mice or 5 rats per cage) and a habituation period of 7 days after transportation was respected before any experimental manipulation was carried out. All surgery was performed under anesthesia and all efforts were made to minimize suffering.

Experimental procedures for obtaining the MPTP mice and 6-OHDA rat models have been previously described (Laloux *et al.*, 2012). Briefly, mice received four intraperitoneal

injections (with 2h intervals) of either saline solution only or 20 mg/kg MPTP (Sigma Aldrich, St Louis, MO, USA). The rats received one cerebral unilateral injection of vehicle or 8µg 6-OHDA (Sigma Aldrich, St Louis, MO, USA) through stereotaxic surgery to the right medial forebrain bundle.

Treatment parameters for rodent models

L-dopa methyl ester hydrochloride (Sigma Aldrich, St Louis, MO, USA) was extemporaneously prepared in saline with 12 mg/kg Benserazide, independent of L-dopa dose (Cenci and Lundblad, 2007). During the treatment regime L-dopa was administered intraperitoneally (i.p.) twice a day at doses previously reported for mice and rats (Espadas *et al.*, 2012; Fornai *et al.*, 2000). Anaerobia-dopamine (A-dopamine, Patent #WO2015173258 A1) was prepared by dissolving in saline (0.9% NaCl, pH 7.4) before the osmotic pump was filled and connected to a brain infusion cannula under an atmosphere that contained 5% hydrogen, 5% carbon dioxide and 90% nitrogen (BACTRON anaerobic/environmental chamber). Before stereotaxic surgery, osmotic pumps were primed under anaerobia for over 4 hours at 37°C. The stability of the A-dopamine solution in osmotic pump at 37°C was checked for up to 30 days using an HPLC assay for dopamine (data not shown).

Treatment over 7 days began one week post MPTP or saline injections in mice. Mice were divided into 13 experimental groups; Saline only, MPTP only, MPTP + A-dopamine (3 to 5 different doses), MPTP + O-dopamine (3 different doses), and MPTP + L-dopa (3 different doses). A- or O-dopamine was administered continuously by i.c.v (1µl/hr; 24h/24h) after surgical cannula-pump (ALZET 2001) implantation in the right lateral ventricle (see supplemental material for details). L-dopa was administered by i.p. twice a day over the same treatment period.

Chronic dopamine treatments (30 days) on rats began 3 weeks after unilateral 6-OHDA or saline cerebral injection. Only 6-OHDA rats displaying more than 5 turns/min in the Apomorphine-induced rotation test were used in the study (75% of the rats). Rats were divided into 6 experimental groups; saline only, 6-OHDA only, 6-OHDA + A-dopamine (3 different doses) and 6-OHDA + L-dopa. After surgical cannula-pump (programmable IPRECIO® SMP200 pumps) implantation on the 6-OHDA lesion side (see supplemental material for details) A-dopamine was administered to the right lateral ventricle by i.c.v at a rate of 3µl/hr for 16h out of 24h (Zeitgeber time 13 to 5). Rats were housed in a 12hr light/12hr dark cycle and the implanted pump was set to deliver dopamine over 16hrs,

predominantly during the active (dark) phase of the rat while it is awake. However this also included part of the resting (light) phase to allow behavioural assessments under treatment (see supplemental image 1 for the time delivery settings). L-dopa was administered by i.p. twice a day over the same treatment period.

Behavioral assessment

Actimetry. Spontaneous motor activity in mice and rats was recorded by an actimeter (Panlab, Barcelona, Spain) over 10 minutes (Laloux *et al.*, 2012). This apparatus and the associated Actitrack software allowed distance travelled, speed and rearing behavior to be measured based on infrared beams obstructions.

Drug-induced rotation test. To assess rotational asymmetry, contralateral rotations over 10 minutes were counted 30 minutes after rats were subcutaneously (s.c.) injected with apomorphine (APOKINON®; 0.5 mg/kg). Only nigro-striatal-lesioned animals performing >5 turns/min were included in the experimental cohorts as these have more than 80% depletion of striatal dopamine terminals (Francardo *et al.*, 2011).

Cylinder test. Rats performed the cylinder test (Schallert *et al.*, 2000) to evaluate spontaneous forelimb lateralization. The number of vertical forepaw explorations on the cylinder wall using the right or left paw was assessed during 3 minutes.

Stepping test. The Stepping test (Olsson *et al.*, 1995) is designed to monitor forelimb akinesia. Rats were gently dragged by the hindquarters across a bench over a distance of 0.90 m in 5 sec. Supportive leg adjustments by the rat were counted over 3 consecutive trials.

Treatments-induced dyskinesia assessment. The principles and classifications of dyskinesia have been standardized and well-described for the rat (Cenci and Lundblad, 2007). Following the injection of L-dopa or during treatment, dyskinesia analysis consisted of scoring rat motor behavior for 1 min every 20 min over 3 h. Based on duration and persistence of the dyskinetic behaviour during the 1-min observation period, abnormal involuntary movements (AIM) were divided into locomotive, axial, forelimbs and orolingual subtypes. For each subtype, a score from 0 to 4 was given to culminate into an overall dyskinesia score for each rat.

Nigro-striatal tyrosine hydroxylase staining and analysis

After treatment and behavioural analysis, mice and rats were sacrificed and 4% paraformaldehyde perfused brains were microscopically sectioned by cryostat for tyrosine

hydroxylase immunochemistry (1:1000; Chemicon International, CA, USA). SN and striatal terminal THr+ neurons were counted by stereological analysis software (Explora Nova, La Rochelle, France)(See supplemental material for details).

Striatum analysis by HPLC

Striatal samples were homogenized (0.1M perchloric acid, 2.6 mM sodium disulfite, 0.7 mM EDTA, 25 ng/ml 3,4-dihydroxybenzylamine) before supernatants were separated by HPLC using a Chromsystems column for Dopamine, DOPAC and 5-cysteinyldopamine or an Uptisphere column for HVA. Glutathione status (i.e. GSSG/ GSH) was also determined chromatographically after derivatization with orthophthalaldehyde was accomplished using isocratic elution on a Symmetry Shield C18 column (Waters SAS, France) (See supplemental material for details).

Statistical analysis

All data were expressed as mean \pm SEM, mostly as a percentage from the saline or vehicle control group. For all parameters, a one-way ANOVA was used to assess group effect, followed by LSD Fisher *post hoc* test. If data did not follow a Gaussian distribution, a Kruskal-Wallis variance analysis was performed, followed by Mann-Whitney *post hoc* test. The threshold for statistical significance was set to $p < 0.05$. All statistical analyses were performed with IBM SPSS Statistics (Version 20).

Results

Dose-related effects of dopamine on dopaminergic neurons in vitro

In order to eliminate the possibility of dopamine being systematically deleterious, we demonstrated *in vitro* that low to moderate dopamine dose ($\leq 3\mu\text{M}$) prevented MPP+ induced neurotoxicity whereas L-dopa was substantially less efficient (Figure 1). Conversely, high doses of either dopamine or L-dopa (10- to 100-fold higher) had moderate to no neuroprotective effect and a very high dose of dopamine (1000-fold higher) increased cell death. The optimal window of neuroprotection for both dopamine and L-dopa was determined to be 0.05 – 0.2 μM .

Deleterious effect of dopamine oxidation avoided by anaerobic preparation of dopamine in vivo

Continuous i.c.v. administration of 240 µg/day O-dopamine induced dopamine oxidation even in the presence of SMBS. This was visually detectable via a brown to black discoloration of the brain's ventricular walls. Despite an improvement in motor activity compared to sham treated mice (Figure 2A), addition of O-dopamine lowered the count of tyrosine hydroxylase positive (TH-ir+) neurons in SNpc (Figure 2B). A reduction in the administered O-dopamine dose (120µg/day) negated the changes to TH-ir+ neuron counts, but strong discoloration of the ventricular walls was still observed in >65% of the mice.

In order to avoid the use of SMBS, due to its poor anti-oxidant properties with additional detrimental effects (Nair *et al.*, 2003), an A-dopamine preparation protocol was developed to maintain the neurotransmitter in an anaerobic environment throughout the filling and pump priming procedures. Similar to O-dopamine with SMBS, high A-dopamine dose (240 µg/day) without SMBS improved motor impairment but was still deleterious to SNpc TH-ir+ neurons (Figure 2B). However, A-dopamine at 120 µg/day without SMBS improved motor activity without neuropathology to the nigro-striatal pathways (Figure 2A). Very low intensity in brown discoloration of the brain's ventricular walls was observed in some mice (~30%).

Functional recovery induced by A-dopamine

The safety profile of A-dopamine was further studied in MPTP-treated mice using a broad dose range (40 - 120 µg/day) and compared to O-dopamine (60 - 120 µg/day) and i.p. L-dopa (twice daily, 25 - 100 mg/day) (Figure 2 C-F). After 7 days, A-dopamine functionally restored mean speed and distance covered by the mouse and had a broader therapeutic index than peripheral L-dopa treatment (i.e. only 50 mg/kg/day L-dopa was beneficial)(Figure 2C-D). Dose-effect on SNpc and striatal TH-ir+ neuron survival by A-dopamine was u-shaped, without hemispheric preference in the SNpc (Figure 2 E-F). The increase in TH-ir+ neurons induced by A-dopamine at 60 and 80 µg/day was determined to be optimal whereas 120µg/day also reversed TH-ir+ terminal loss in striatum. Conversely, neither O-dopamine nor L-dopa prevented reduced TH-ir counts after MPTP in the SNpc and striatum.

Diffusion and metabolism of A-dopamine within the brain

Lateral ventricular administration of 80 and 120 µg/day A-dopamine demonstrated good diffusion into the ipsilateral striatum post MPTP intoxication. Similar results were observed upon peripheral L-dopa administered at 50 and 100 mg/day, with 120 µg/day A-dopamine and 100 mg/day L-dopa having comparable maximal diffusion (Figure 3A).

The reduction in DOPAC and HVA metabolites caused by MPTP in the striatum (75% loss) was significantly restored by 60 to 120 µg/day of A-dopamine and in a dose-dependent manner with L-dopa (Figure 3B-C). Of note, A-dopamine preferentially increased HVA whereas L-dopa favored a DOPAC increase, potentially revealing alternate metabolism pathways.

As bilateral distribution from the lateral ventricle through the third ventricle to both striatum is not evident in mice, A-dopamine did not alter the contralateral striatal level of dopamine or metabolites (except for the highest dose which significantly increased HVA).

Changes to A-dopamine oxidative metabolism

The oxidative metabolism of dopamine was determined by 5-cysteinyldopamine; a glutathione-dependent covalent modification of dopamine quinones derived from dopamine oxidation (Chen *et al.*, 2008). Levels were not modified with doses of A-dopamine below 120 µg/day (i.e. ≤ 0.3 nmol/mg) or with the peripheral L-dopa treatment (undetectable) (Suppl. Table 1). Glutathione was strongly oxidized by MPTP intoxication (as indicated by low GSH/GSSG ratio) but the GSH/GSSG ratio was significantly increased by both A-dopamine and L-dopa treatments. This suggested that both were equally protective in regard to the redox state of dopaminergic neurons.

Lack of tachyphylaxia following chronic A-dopamine stimulation in 6-OHDA rats

In 6-OHDA treated rats, A-dopamine was chronically administered by i.c.v for 30 days (16h/day) at 3 doses (1, 2 and 3 mg/day). This regime was compared behaviorally to peripherally administered L-dopa (6 mg/kg twice daily) over the same time period. For A-dopamine, 'stepping' and the 'cylinder' tests were consistent with actimetry analysis. At both 15 and 30 days post-neurotoxin injection, a dose response effect was observed for A-dopamine, whereby 1mg/day was considered ineffective, 2mg/day restored the mean locomotive speed and distance of the rat and 3mg/day induced over-activity (Figure 4A-D).

Observationally, it was noted that differences between 2 and 3 mg/day at 15 days were reduced after 30 days of treatment. As previously reported 6-OHDA rats responded well to L-dopa treatment in all three motor tests (Laloux *et al.*, 2012) despite an over compensation after 30 days of treatment of the contralateral paw in the cylinder and stepping test (Figure 4C & D).

Lack of dyskinesia and dopaminergic sensitization following A-dopamine stimulation

Chronic peripheral treatment with L-dopa (6 mg/kg twice daily for 30 days) induced a consistent and high dyskinesia score compared to sham or 6-OHDA-treated rats (Table 1). However throughout the treatment period, all doses of A-dopamine (1-3mg/day) produced minimal abnormal locomotive movements and dyskinesias was undetectable (Video 1). Moreover, as previously reported (Bordet *et al.*, 2000), by the end of the 30 day treatment period behavioral dopaminergic sensitization associated with dyskinesia was evident in L-dopa treatment (Figure 4E). Conversely, a reduced number of apomorphine-induced rotations were observed with A-dopamine administration.

Good safety profile of A-dopamine

Neither L-dopa or A-dopamine had supplementary deleterious effects on the remaining 10% TH-ir+ neurons after ipsilateral 6-OHDA injection (Figure 4G & H). Highest doses of A-dopamine may even have had a positive impact (Figure 4G). A significant body weight gain was observed in higher doses of A-dopamine and may be attributed to dopamine effect on motivation to eat (*via* its action on mesolimbic system) or an orexigen effect (*via* the hypothalamic system). In L-dopa treated rats this gain was reduced after 30 days compared to shams (Figure 4F) and could be associated with higher daily energy expenditure as a result from the observed dyskinesias. No overall harmful effects could be attributed to body weight changes and no anatomopathological alteration of heart, liver, pancreas, spleen, kidney, spinal cord, eye, and brain were observed after 30 days of either treatment.

Discussion

Results obtained in these three different models of PD demonstrate a promising therapeutic regime for A-dopamine treatment. *In vitro*, a positive effect of dopamine was observed on LHUMES cell survival. *In vivo*, A-dopamine restored motor function and

induced a dose dependent increase of nigro-striatal tyrosine hydroxylase positive neuron survival in mice after 7 days of MPTP insult, suggesting a strong safety profile that was not evident with either O-dopamine or L-dopa. In a chronic rat model using 6-OHDA-lesioning, continuous circadian i.c.v injection of A-dopamine over 30 days also improved motor activity without occurrence of tachyphylaxia. Significantly, A-dopamine did not induced dyskinesia or behavioral sensitization as observed with peripheral L-dopa treatment.

Similar to L-dopa treatment in previous clinical and preclinical studies, inconsistencies are reported in the use of dopamine, whereby high doses are described as neurotoxic (Hastings *et al.*, 1996) but sub-toxic concentrations have neuroprotective and neurotrophic effects (Jia *et al.*, 2008). We confirm that the positive impact of dopamine on TH-ir+ neurons of the nigro-striatal pathways was predominantly dependent on dose, but the oxidation state of dopamine is also paramount. As well as illustrating that O-dopamine was detrimental to neurons, higher A-dopamine concentrations in the presence of MPTP also induced significant neurotoxic 5-cysteinyl-DA production. However a low A-dopamine dose promoted TH-ir+ neuronal counts with no evidence of oxidized dopamine.

To our knowledge, this is the first to describe such a SNpc and striatal TH-ir+ neuronal plasticity with dopamine administration. We suggest that this could be explained by a culmination of events. Low A-dopamine dose prevented TH stained neuronal death caused by synaptic inactivity (Jeon *et al.*, 1995), restored dopaminergic cell markers required for maintained dopamine production (Datla *et al.*, 2001), scavenged rather than promoted ROS formation (Agil *et al.*, 2006) and may have enabled a switch in striatal neurons from a serotonergic to dopaminergic phenotype (Carta *et al.*, 2007).

A viable optimal therapeutic regime would be to continuously compensate the deficit in dopamine that mediates neuronal communication within the SNpc. A continuous non-pulsatile i.c.v administration better mimics the physiological released of dopamine caused by the tonic background activity of SNpc neurons (Olanow *et al.*, 2006). In animal models of PD, several studies have proven the efficacy of continuous dopamine infusion. Hargraves and Freed (1987) showed that striatal injection of 12 or 120 µg/day dopamine with SMBS (during 13 days) reduced locomotive abnormalities, whereas others studies confirmed this result with alternative administration parameters (e.g. i.c.v injection, dose at 240 µg/day or time over 7 days) (De Yebenes *et al.*, 1987; Kroin *et al.*, 1991). The first human case report (Venna *et al.*, 1984) described a good tolerance to dopamine infusion over 1 year. A subsequent human case report (Horne *et al.*, 1989) supports our current data by illustrating that long-term i.c.v.

dopamine provides a smooth control of motor symptoms. However until now, concerns regarding dopamine oxidation and patient tachyphylaxia have restricted further development. Of note, PD patients from previous studies received O-dopamine and at the same dose throughout a 24 hours cycle. Prior experience obtained from the use of an apomorphine pump and duodopa® has identified the need to differentiate between diurnal and nocturnal minimum efficient dose in order to avoid worsening motor fluctuations (Devos and French DUODOPA study group, 2009; Drapier *et al.*, 2016).

In summary, far from being deleterious, we observe that when dopamine levels and oxidative state are harnessed it can be beneficial to neuron survival. Minimizing dopamine administrative dose, focusing delivery location and restricting the oxidative states all had a positive impact on the nigro-striatal pathways. Long-term i.c.v of A-dopamine using a circadian cycle also dramatically reduced the detrimental side effects of the current therapeutic regime of L-dopa (i.e. L-dopa related complications with dyskinesia).

Acknowledgments

The authors wish to thank Jean Christophe Corvol and Erwan Bezard for helpful comments on the manuscript and the functional exploration platform for rodent behavior experiments (Federation of Neurosciences, University of Lille).

Authors's roles

Ch.L., J.C.D., D.D. conceived, managed the project and designed experiments; Ch.L., F.G., Cé.L., K.T. performed most experiments and analysed data; B.DV, A.J., M.P., G.G., N.R. helped for the experiments. Ch.L., J.C.D., D.D., J.A.D. wrote the manuscript text and prepared figures; C.M., R.B. review and critique of the paper.

Full Financial Disclosures of all Authors for the Past Year

The authors have no financial disclosures to make or potential conflicts of interest to report in relation to this study. Caroline Moreau serves on the Scientific Advisory Board for Aguetant. Régis Bordet receives funding from the French Ministry of Research. He has received various honoraria from pharmaceutical companies for consultancy and lectures at symposia. David Devos serves on the Scientific Advisory Board for Apopharma, Novartis, GSK, Orkyn,

Britannia Pharmaceuticals, Abbvie and Aguetant and has received PHRC grants from the French Ministry of Health and research funding from France Parkinson and ARSLA charity. He has received various honoraria from pharmaceutical companies for consultancy and lectures on Parkinson's disease at symposia. Charlotte Laloux, Flore Gouel, Cédric Lachaud, Kelly Timmerman, Bruce DoVan, Aurélie Jonneaux, Maud Petrault, Guillaume Garçon, Nathalie Rouaix, James Duce and Jean Christophe Devedjian have no disclosures to report.

References list

- Agil, A., Durán, R., Barrero, F., Morales, B., Araúzo, M., Alba, F., Miranda, M.T., Prieto, I., Ramírez, M., Vives, F., 2006. Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa. *J. Neurol. Sci.* 240, 31–36.
- Bordet, R., Ridray, S., Schwartz, J.C., Sokoloff, P., 2000. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. *Eur. J. Neurosci.* 12, 2117–2123.
- Carta, M., Carlsson, T., Kirik, D., Björklund, A., 2007. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. *Brain* 130, 1819–1833.
- Cenci, M.A., Lundblad, M., 2007. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. *Curr Protoc Neurosci* Chapter 9, Unit 9.25.
- Chaudhuri, K.R., Schapira, A.H.V., 2009. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurol* 8, 464–474.
- Chen, L., Ding, Y., Cagniard, B., Van Laar, A.D., Mortimer, A., Chi, W., Hastings, T.G., Kang, U.J., Zhuang, X., 2008. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. *J. Neurosci.* 28, 425–433.
- Ciesielska, A., Sharma, N., Beyer, J., Forsayeth, J., Bankiewicz, K., 2015. Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats. *PLoS ONE* 10, e0122708.
- Datla, K.P., Blunt, S.B., Dexter, D.T., 2001. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. *Mov. Disord.* 16, 424–434.
- De Lau, L.M.L., Breteler, M.M.B., 2006. Epidemiology of Parkinson's disease. *Lancet Neurol* 5, 525–535.
- Devos, D., French DUODOPA Study Group, 2009. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. *Mov. Disord.*

24, 993–1000.

- De Yebenes, J.G., Fahn, S., Lovelle, S., Jackson-Lewis, V., Jorge, P., Mena, M.A., Reiriz, J., Bustos, J.C., Magariños, C., Martinez, A., 1987. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease. *Mov. Disord.* 2, 143–158.
- Drapier, S., Eusebio, A., Degos, B., Vérin, M., Durif, F., Azulay, J.P., Viallet, F., Rouaud, T., Moreau, C., Defebvre, L., Fraix, V., Tranchant, C., Andre, K., Courbon, C.B., Roze, E., Devos, D., 2016. Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study. *J. Neurol.* 263, 1111–1119.
- Espadas, I., Darmopil, S., Vergaño-Vera, E., Ortiz, O., Oliva, I., Vicario-Abejón, C., Martín, E.D., Moratalla, R., 2012. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. *Neurobiol. Dis.* 48, 271–281.
- Fahn, S., Parkinson Study Group, 2005. Does levodopa slow or hasten the rate of progression of Parkinson's disease? *J. Neurol.* 252 Suppl 4, IV37–IV42.
- Fornai, F., Battaglia, G., Gesi, M., Giorgi, F.S., Orzi, F., Nicoletti, F., Ruggieri, S., 2000. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. *Brain Res.* 887, 110–117.
- Francardo, V., Recchia, A., Popovic, N., Andersson, D., Nissbrandt, H., Cenci, M.A., 2011. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. *Neurobiol. Dis.* 42, 327–340.
- Gershanik, O., Jenner, P., 2012. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. *European Journal of Neurology* 19, 1502–1508.
- Hargraves, R., Freed, W.J., 1987. Chronic intrastriatal dopamine infusions in rats with unilateral lesions of the substantia nigra. *Life Sci.* 40, 959–966.
- Hastings, T.G., Lewis, D.A., Zigmond, M.J., 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. *Proc. Natl. Acad. Sci. U.S.A.* 93, 1956–1961.
- Horne, M.K., Butler, E.G., Gilligan, B.S., Wodak, J., Stark, R.J., Brazenor, G.A., 1989. Intraventricular infusion of Dopamine in Parkinson's disease. *Ann. Neurol.* 26, 792–794.
- Jeon, B.S., Jackson-Lewis, V., Burke, R.E., 1995. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. *Neurodegeneration* 4, 131–137.
- Jia, Z., Zhu, H., Misra, B.R., Li, Y., Misra, H.P., 2008. Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic neuroprotection. *Neurochem. Res.* 33, 2197–2205.

- Kroin, J.S., Kao, L.C., Zhang, T.J., Penn, R.D., Klawans, H.L., Carvey, P.M., 1991. Dopamine distribution and behavioral alterations resulting from dopamine infusion into the brain of the lesioned rat. *J. Neurosurg.* 74, 105–111.
- Laloux, C., Petrault, M., Lecointe, C., Devos, D., Bordet, R., 2012. Differential susceptibility to the PPAR- γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. *Pharmacol. Res.* 65, 514–522.
- Nair, B., Elmore, A.R., Cosmetic Ingredients Review Expert Panel, 2003. Final report on the safety assessment of sodium sulfite, potassium sulfite, ammonium sulfite, sodium bisulfite, ammonium bisulfite, sodium metabisulfite and potassium metabisulfite. *Int. J. Toxicol.* 22 Suppl 2, 63–88.
- Olanow, C.W., Obeso, J.A., Stocchi, F., 2006. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. *Nat Clin Pract Neurol* 2, 382–392.
- Olsson, M., Nikkhah, G., Bentlage, C., Björklund, A., 1995. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. *J. Neurosci.* 15, 3863–3875.
- Paladini, C.A., Roeper, J., 2014. Generating bursts (and pauses) in the dopamine midbrain neurons. *Neuroscience* 282C, 109–121.
- Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L., Bland, S.T., 2000. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. *Neuropharmacology* 39, 777–787.
- Venna, N., Sabin, T.D., Ordia, J.I., Mark, V.H., 1984. Treatment of severe Parkinson's disease by intraventricular injection of dopamine. *Appl Neurophysiol* 47, 62–64.

Figure legends

Figure 1: Dose-related effects of dopamine on LUHMES dopaminergic neurons. Overall LUHMES viability was greater after A-dopamine compared to L-dopa treatment (0.01 – 300 μ M). Significant differences * *vs.* saline condition, # *vs.* MPP+ condition, § between the dopamine and L-dopa conditions, $p < 0.05$ (Mann-Whitney comparison test).

Figure 2: Neuroprotection of nigro-striatal pathway and functional recovery induced by cerebral A-dopamine infusion in MPTP mice. Distance covered in actimetry arena (**A**) and TH-ir+ neuronal count in SNpc (**B**) was measured in MPTP mice after 7 days of dopamine treatment, either supplemented with SMBS or prepared anaerobically. To determine the optimal dose of each treatment on motor function post-MPTP insult, distance covered (**C**) and mean speed (**D**) within the actimetry arena was assessed after i.p. L-dopa (25-100mg/kg/day) or i.c.v. dopamine prepared anaerobically (A-dopamine)(40-120 μ g/day) or aerobically (O-dopamine) (60-120 μ g/day). Neuropathological outcomes were also assessed within the same parameters by measuring ipsilateral and contralateral TH-ir+ optical density in dorsal striatum (**E**) and TH-ir+ neuronal counts in SNpc (**F**). Data are expressed in percentage from saline mice, means \pm SEM (n=6/group for **A&B**, 12/group for **C&D**, 8/group for **E&F**). Significant differences * *vs.* saline mice, # *vs.* untreated MPTP mice, $p < 0.05$ (one-way ANOVA and LSD Fisher post-hoc tests or Mann-Whitney comparison test).

Figure 3: Diffusion and metabolization of striatal A-dopamine. Within the striatum, dopamine (**A**) 3,4 dihydroxyphenylacetic acid (DOPAC) (**B**) and homovanillic acid (HVA) (**C**) were measured in each hemisphere after 7 days of L-dopa or anaerobic dopamine (A-dopamine). Ipsilateral and contralateral represents the side in which i.c.v. dopamine was infused. Data are expressed in percentage from saline mice, means \pm SEM (n=6 animal per group). * *vs.* saline mice, # *vs.* untreated MPTP mice, $p < 0.05$ (one-way ANOVA and LSD Fisher post-hoc tests).

Figure 4: Functional recovery without tachyphylaxia or dopaminergic sensitization following chronic circadian A-dopamine stimulation in 6-OHDA rats. 6-OHDA rats were administered i.p. L-dopa (12 mg/kg/day) or i.c.v. anaerobically prepared dopamine (A-dopamine; 1-3 mg/day) and motor skills assessed after 15 or 30 days. Distance covered (**A**) and mean speed (**B**) in the actimetry arena as well as right paw support in the cylinder test (**C**) and right step adjustment in the stepping test (**D**) were evaluated. All data was compared to vehicle control set at 100% within the actimetry arena (**A&B**) or 50% representing equal

forelimb preference (**C&D**). For apomorphine induced rotation, measurements were taken immediately after 6-OHDA insult but before treatment (D0) as well as 30 days after treatment (D30) in the same treatment parameters (**E**). Rat body weight gain during the 30 days of treatment (**F**) as well as TH-ir+ optical density in dorsal striatum (ipsilateral and contralateral) (**G**) and TH-ir+ neuronal count in SNpc (**H**) were also evaluated. All data are expressed in percentage from Vehicle rats, means \pm SEM (n=10/group). Significant differences * vs. vehicle rats, # vs. untreated 6-OHDA rats, $p < 0.05$ (one-way ANOVA and LSD Fisher post-hoc tests or Mann-Whitney comparison test).

Table 1: Lack of dyskinesia during cerebral infusion of A-dopamine in 6-OHDA rats.

The table differentiates dyskinesia scores (Limb, axial and orolingual) and abnormal involuntary movements (AIM) in locomotion each 20 minutes over 2 hours. At 7, 15 and 30 days of treatment, measurement began 30 min after i.p. L-dopa or during A-dopamine i.c.v. Data are expressed in means \pm SEM (n=10 animal per group). Significant differences * vs. untreated 6-OHDA rats, # vs. L-dopa treated 6-OHDA rats, $p < 0.05$ (non-parametric Kruskal-Wallis variance analysis and Mann-Whitney comparison).

Supplementary Table 1: Dopamine autoxidation and GSH/GSSG ratio in the striatum of MPTP mice after A-dopamine or L-dopa treatments. A-dopamine (A-DA) doses are expressed in $\mu\text{g/day}$ and L-dopa (LD) in mg/kg/day . Data are expressed in mean \pm SEM (n=8). Significant differences * vs. saline mice, # vs. untreated MPTP mice, $p < 0.05$ (non-parametric Kruskal-Wallis variance analysis and Mann-Whitney comparison)

Figure 1:




Figure 2:




Figure 3




Figure 4:




Table 1

Exp time	6-OHDA rat Groups	Dyskinesia types			Dyskinesias score	Locomotive AIM
		Limb	Axial	Orolingual		
D7	Vehicle	0	0	0	0	0
	L-dopa	11.1 ± 1.99 *	8.4 ± 1.67 *	9.9 ± 1.66 *	29.40 ± 5.25 *	4.8 ± 1.39 *
	A-DA 1 mg/d	0	0	0	0	1 ± 1 #
	A-DA 2 mg/d	0	0	0	0	2.14 ± 0.91
	A-DA 3 mg/d	0	0	0	0	5.4 ± 1.12 *
D15	Vehicle	0	0	0	0	0
	L-dopa	12.2 ± 1.67 *	7.9 ± 1.38 *	10.9 ± 1.75 *	31.0 ± 4.63 *	6.1 ± 1.0 *
	A-DA 1 mg/d	0	0	0	0	0.7 ± 0.7 #
	A-DA 2 mg/d	0	0	0	0	1.56 ± 0.67 #
	A-DA 3 mg/d	0	0	0	0	2.71 ± 1.02 #
D30	Vehicle	0	0	0	0	0
	L-dopa	13.6 ± 2.03 *	8.6 ± 1.85 *	13.5 ± 2.15 *	35.7 ± 5.89 *	7.2 ± 1.33 *
	A-DA 1 mg/d	0	0	0	0	1 ± 1 #
	A-DA 2 mg/d	0	0	0	0	2.25 ± 1.31 #
	A-DA 3 mg/d	0	0	0	0	0.6 ± 0.4 #

Highlights

Continuous intracerebroventricular infusion of anaerobic dopamine is safe in models

It restores motor function and prevents from dyskinesia in PD models

Infusion of anaerobic of dopamine avoids tachyphylaxia with large therapeutic index

Brain administration of dopamine is new therapeutic concept for Parkinson's disease

Could be indicated for patients suffering from L-dopa related complications?